**The Ovation**

On June 5, 2022 thousands of oncologists were packed into a convention center auditorium in Chicago to hear about a new drug that might revolutionize the treatment for metastatic breast cancer.

Then, the results were announced of a clinical trial involving almost 600 patients, all of whom had metastatic breast cancer. The new drug they received—known as Enhertu—doubled the survival time.

The crowd gave a thunderous standing ovation.

New hope had arrived.

**The HER2 Puzzle**

For decades a protein known as HER2 was observed on the surface of breast cancer cells—sometimes in abundance (HER2-positive) and more often with seemingly zero presence (HER2-negative.)

For years the HER2-positive group was treated with a targeted therapy, Herceptin, but it was not effective if the metastatic breast cancer patient was classified as HER2-negative, in which case their only option was chemo. The nationwide breakdown was:

<table>
<thead>
<tr>
<th>HER2 Status</th>
<th>% Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive</td>
<td>20%</td>
</tr>
<tr>
<td>Negative</td>
<td>80%</td>
</tr>
</tbody>
</table>

It is a two-part drug. One acts as a navigator, seeking out cancer cells that express only a minimal amount of HER2.

Then a second part is a newly formulated chemo that seeps through the cell surface and bathes the cancer cell interior with a poison.

**And the Experts Say . . .**

“**This is a new standard of care. . . it affects a huge number of patients.**”
E. Winer, MD Yale

“**Phenomenally spectacular**”
Head of Daiichi Pharma

They’ve created a new category of breast cancer, HER-2-Low . . . It will expand the patient population who benefits from HER-2-targeted therapy.

American Society of Clinical Oncology

Fighting Chance has offices in Sag Harbor and at the Phillips Family Cancer Center in Southampton.

For more details, or information please call 631 725 4646.
Visit our website at www.fightingchance.org